Patents Assigned to Crystal Bioscience Inc.
  • Patent number: 11602136
    Abstract: A transgenic non-human animal is provided. In certain embodiments, the animal comprises a genome comprising an immunoglobulin heavy chain locus comprising: a) a transcribed gene encoding a fusion protein comprising, from N-terminus to C-terminus: i. a scaffold comprising a first binding domain; and ii. a heavy chain constant region operably linked to the scaffold; wherein the scaffold is capable of specifically binding to a target in the absence of additional polypeptides; and b) a plurality of pseudogenes that are operably linked to the transcribed gene and that donate, by gene conversion, nucleotide sequence to the part of the transcribed gene that encodes the binding domain.
    Type: Grant
    Filed: January 6, 2020
    Date of Patent: March 14, 2023
    Assignee: CRYSTAL BIOSCIENCE INC.
    Inventor: William Don Harriman
  • Patent number: 11542319
    Abstract: A transgenic chicken comprising an inactivated heavy immunoglobulin gene and/or inactivated light chain immunoglobulin gene is provided, as well as cells and targeting vectors for making the same.
    Type: Grant
    Filed: May 15, 2020
    Date of Patent: January 3, 2023
    Assignee: CRYSTAL BIOSCIENCE INC.
    Inventors: Philip A. Leighton, William Don Harriman, Robert Etches
  • Patent number: 11337409
    Abstract: This disclosure provides, among other things, strategies for minimizing antibody diversification in a transgenic animal that uses gene conversion for antibody diversification. In some embodiments, the animal may comprise a genome comprising an endogenous immunoglobulin light chain locus comprising: (a) a functional immunoglobulin light chain gene comprising a nucleic acid encoding a light chain variable region; and (b) a plurality of pseudogenes that are operably linked to the functional immunoglobulin light chain gene and that donate, by gene conversion, nucleotide sequence to the nucleic acid encoding a light chain variable region, wherein the pseudogenes are upstream or downstream of the functional immunoglobulin light chain gene and encode the same amino acid sequence as the light chain variable region of the functional immunoglobulin light chain gene of (a). In other embodiments, the locus may have a tandem array of coding sequences for the light chain.
    Type: Grant
    Filed: June 5, 2019
    Date of Patent: May 24, 2022
    Assignee: CRYSTAL BIOSCIENCE INC.
    Inventors: Philip A. Leighton, William Don Harriman, Robert Etches
  • Patent number: 11033009
    Abstract: This disclosure provides, among other things, a transgenic animal and a method of using the same to make antibodies that have a common light chain. In certain embodiments, the transgenic animal may comprising a genome comprising a common light chain transgene, wherein the common light chain transgene comprises a non-immunoglobulin light-chain promoter and a common light-chain coding sequence. In certain embodiments, the common light chain is constitutively expressed.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: June 15, 2021
    Assignee: CRYSTAL BIOSCIENCE INC.
    Inventors: William Don Harriman, Robert Etches, Philip A. Leighton
  • Patent number: 10687519
    Abstract: A transgenic animal is provided. In certain embodiments, the transgenic animal comprises a genome comprising: an immunoglobulin light chain locus comprising: a) a functional immunoglobulin light chain gene comprising a transcribed variable region encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of 2 to 5 different amino acids; and ii. a light chain framework; and, operably linked to the functional immunoglobulin light chain gene: b) a plurality of pseudogene light chain variable regions each encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of the same 2 to 5 different amino acids as the CDRs of the functional gene; and ii. a light chain framework that is identical in amino acid sequence to the light chain framework of the transcribed variable region.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: June 23, 2020
    Assignee: CRYSTAL BIOSCIENCE INC.
    Inventors: William Don Harriman, Robert Etches, Philip A. Leighton
  • Patent number: 10689433
    Abstract: A transgenic chicken comprising an inactivated heavy immunoglobulin gene and/or inactivated light chain immunoglobulin gene is provided, as well as cells and targeting vectors for making the same.
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: June 23, 2020
    Assignee: CRYSTAL BIOSCIENCE INC.
    Inventors: Philip A. Leighton, William Don Harriman, Robert Etches
  • Patent number: 10555508
    Abstract: A transgenic non-human animal is provided. In certain embodiments, the animal comprises a genome comprising an immunoglobulin heavy chain locus comprising: a) a transcribed gene encoding a fusion protein comprising, from N-terminus to C-terminus: i. a scaffold comprising a first binding domain; and ii. a heavy chain constant region operably linked to the scaffold; wherein the scaffold is capable of specifically binding to a target in the absence of additional polypeptides; and b) a plurality of pseudogenes that are operably linked to the transcribed gene and that donate, by gene conversion, nucleotide sequence to the part of the transcribed gene that encodes the binding domain.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: February 11, 2020
    Assignee: CRYSTAL BIOSCIENCE INC.
    Inventor: William Don Harriman
  • Patent number: 10362770
    Abstract: A transgenic animal is provided. In certain embodiments, the transgenic animal comprises a genome comprising: an immunoglobulin light chain locus comprising: a) a functional immunoglobulin light chain gene comprising a transcribed variable region encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of 2 to 5 different amino acids; and ii. a light chain framework; and, operably linked to the functional immunoglobulin light chain gene: b) a plurality of pseudogene light chain variable regions each encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of the same 2 to 5 different amino acids as the CDRs of the functional gene; and ii. a light chain framework that is identical in amino acid sequence to the light chain framework of the transcribed variable region.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: July 30, 2019
    Assignee: Crystal Bioscience Inc.
    Inventors: William Don Harriman, Robert Etches, Philip A. Leighton
  • Patent number: 10172334
    Abstract: A transgenic animal is provided. In certain embodiments, the transgenic animal comprises a genome comprising: an immunoglobulin light chain locus comprising: a) a functional immunoglobulin light chain gene comprising a transcribed variable region encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of 2 to 5 different amino acids; and ii. a light chain framework; and, operably linked to the functional immunoglobulin light chain gene: b) a plurality of pseudogene light chain variable regions each encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of the same 2 to 5 different amino acids as the CDRs of the functional gene; and ii. a light chain framework that is identical in amino acid sequence to the light chain framework of the transcribed variable region.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: January 8, 2019
    Assignee: Crystal Bioscience Inc.
    Inventors: William Don Harriman, Robert Etches, Philip A. Leighton
  • Patent number: 10010058
    Abstract: A transgenic animal is provided. In certain embodiments, the transgenic animal comprises a genome comprising: an immunoglobulin light chain locus comprising: a) a functional immunoglobulin light chain gene comprising a transcribed variable region encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of 2 to 5 different amino acids; and ii. a light chain framework; and, operably linked to the functional immunoglobulin light chain gene: b) a plurality of pseudogene light chain variable regions each encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of the same 2 to 5 different amino acids as the CDRs of the functional gene; and ii. a light chain framework that is identical in amino acid sequence to the light chain framework of the transcribed variable region.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: July 3, 2018
    Assignee: Crystal Bioscience Inc.
    Inventors: William Don Harriman, Robert Etches, Philip A. Leighton
  • Patent number: 9982062
    Abstract: A transgenic non-human animal is provided. In certain embodiments, the animal comprises a genome comprising an immunoglobulin heavy chain locus comprising: a) a transcribed gene encoding a fusion protein comprising, from N-terminus to C-terminus: i. a scaffold comprising a first binding domain; and ii. a heavy chain constant region operably linked to the scaffold; wherein the scaffold is capable of specifically binding to a target in the absence of additional polypeptides; and b) a plurality of pseudogenes that are operably linked to the transcribed gene and that donate, by gene conversion, nucleotide sequence to the part of the transcribed gene that encodes the binding domain.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: May 29, 2018
    Assignee: CRYSTAL BIOSCIENCE INC.
    Inventor: William Don Harriman
  • Patent number: 9809642
    Abstract: A transgenic chicken comprising an inactivated heavy immunoglobulin gene and/or inactivated light chain immunoglobulin gene is provided, as well as cells and targeting vectors for making the same.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: November 7, 2017
    Assignee: Crystal Bioscience Inc.
    Inventors: Philip A. Leighton, William Don Harriman, Robert Etches
  • Patent number: 9644178
    Abstract: A sustained culture of isolated avian gonocytes is provided, as well as a method of making and using the same. A chimeric avian containing an isolated gonocyte and a transgenic avian produced using the chimeric avian are also provided. The cell and method may be employed to make, among other things, transgenic avian that produce a heterologous protein, e.g., a therapeutic protein.
    Type: Grant
    Filed: September 16, 2014
    Date of Patent: May 9, 2017
    Assignee: CRYSTAL BIOSCIENCE, INC.
    Inventors: Marie-Cecile van de Lavoir, Robert Etches
  • Patent number: 9549538
    Abstract: A transgenic animal is provided. In certain embodiments, the transgenic animal comprises a genome comprising: an immunoglobulin light chain locus comprising: a) a functional immunoglobulin light chain gene comprising a transcribed variable region encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of 2 to 5 different amino acids; and ii. a light chain framework; and, operably linked to the functional immunoglobulin light chain gene: b) a plurality of pseudogene light chain variable regions each encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of the same 2 to 5 different amino acids as the CDRs of the functional gene; and ii. a light chain framework that is identical in amino acid sequence to the light chain framework of the transcribed variable region.
    Type: Grant
    Filed: June 21, 2016
    Date of Patent: January 24, 2017
    Assignee: CRYSTAL BIOSCIENCE, INC.
    Inventors: William Don Harriman, Robert Etches, Philip A. Leighton
  • Patent number: 9404125
    Abstract: A transgenic animal is provided. In certain embodiments, the transgenic animal comprises a genome comprising: an immunoglobulin light chain locus comprising: a) a functional immunoglobulin light chain gene comprising a transcribed variable region encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of 2 to 5 different amino acids; and ii. a light chain framework; and, operably linked to the functional immunoglobulin light chain gene: b) a plurality of pseudogene light chain variable regions each encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of the same 2 to 5 different amino acids as the CDRs of the functional gene; and ii. a light chain framework that is identical in amino acid sequence to the light chain framework of the transcribed variable region.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: August 2, 2016
    Assignee: CRYSTAL BIOSCIENCE, INC.
    Inventors: William Don Harriman, Robert Etches, Phil Leighton
  • Patent number: 9394372
    Abstract: A transgenic non-human animal is provided. In certain embodiments, the animal comprises a genome comprising an immunoglobulin heavy chain locus comprising: a) a transcribed gene encoding a fusion protein comprising, from N-terminus to C-terminus: i. a scaffold comprising a first binding domain; and ii. a heavy chain constant region operably linked to the scaffold; wherein the scaffold is capable of specifically binding to a target in the absence of additional polypeptides; and b) a plurality of pseudogenes that are operably linked to the transcribed gene and that donate, by gene conversion, nucleotide sequence to the part of the transcribed gene that encodes the binding domain.
    Type: Grant
    Filed: October 16, 2012
    Date of Patent: July 19, 2016
    Assignee: CRYSTAL BIOSCIENCE INC.
    Inventor: William Don Harriman
  • Patent number: 9380769
    Abstract: A transgenic chicken comprising an inactivated heavy immunoglobulin gene and/or inactivated light chain immunoglobulin gene is provided, as well as cells and targeting vectors for making the same.
    Type: Grant
    Filed: May 23, 2012
    Date of Patent: July 5, 2016
    Assignee: Crystal Bioscience Inc.
    Inventors: Phil Leighton, William Don Harriman, Robert Etches
  • Patent number: 8865462
    Abstract: A sustained culture of isolated avian gonocytes is provided, as well as a method of making and using the same. A chimeric avian containing an isolated gonocyte and a transgenic avian produced using the chimeric avian are also provided. The cell and method may be employed to make, among other things, transgenic avian that produce a heterologous protein, e.g., a therapeutic protein.
    Type: Grant
    Filed: January 7, 2011
    Date of Patent: October 21, 2014
    Assignee: Crystal Bioscience Inc.
    Inventors: Marie-Cecile van de Lavoir, Robert Etches
  • Publication number: 20140082759
    Abstract: A transgenic chicken comprising an inactivated heavy immunoglobulin gene and/or inactivated light chain immuno -well as globulin gene is provided, as we cells and targeting vectors for making the same.
    Type: Application
    Filed: May 23, 2012
    Publication date: March 20, 2014
    Applicant: Crystal Bioscience Inc.
    Inventors: Phil Leighton, William Don Harriman, Robert Etches
  • Publication number: 20140068796
    Abstract: A transgenic animal is provided. In certain embodiments, the transgenic animal comprises a genome comprising: an immunoglobulin light chain locus comprising: a) a functional immunoglobulin light chain gene comprising a transcribed variable region encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of 2 to 5 different amino acids; and ii. a light chain framework; and, operably linked to the functional immunoglobulin light chain gene: b) a plurality of pseudogene light chain variable regions each encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of the same 2 to 5 different amino acids as the CDRs of the functional gene; and ii. a light chain framework that is identical in amino acid sequence to the light chain framework of the transcribed variable region.
    Type: Application
    Filed: October 18, 2013
    Publication date: March 6, 2014
    Applicant: CRYSTAL BIOSCIENCE, INC.
    Inventors: William Don Harriman, Robert Etches, Phil Leighton